Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer's disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future: coverage, quality and costs now and in the future. Alzheimer’s Dis. Int. (2016). https://www.alz.co.uk/research/world-report-2016 •• Provides a unique global view of Alzheimer's disease, including patterns, causes and treatment.
  Google Scholar
• 2. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J. Cent. Nerv. Syst. Dis. 12, 1–12 (2020).
  Google Scholar
• 3. Klimova B, Maresova P, Valis M et al. Alzheimer's disease and language impairments: social intervention and medical treatment. Clin. Interv. Aging 10, 1401 (2015).
  Medline CASGoogle Scholar
• 4. Maresova P, Klimova B, Novotny M et al. Alzheimer's and Parkinson's diseases: expected economic impact on Europe – a call for a uniform European strategy. J. Alzheimers Dis. 54(3), 1123–1133 (2016).
  MedlineGoogle Scholar
• 5. Morris JC. Classification of dementia and Alzheimer's disease. Acta Neurol. Scand. 94(Suppl. 165), S41–S50 (1996).
  Google Scholar
• 6. Klimova B, Kuca K. Speech and language impairments in dementia. J. Appl. Biomed. 14(2), 97–103 (2016).
  Google Scholar
• 7. Nieoullon A. Neurodegenerative diseases and neuroprotection: current views and prospects. J. Appl. Biomed. 9(4), 173–183 (2011).
  Google Scholar
• 8. Von Schnehen A, Hobeika L, Huvent-Grelle D et al. Sensorimotor synchronization in healthy aging and neurocognitive disorders. Front. Psychol. 13, 838511 (2022).
  MedlineGoogle Scholar
• 9. Association AS. Alzheimer's disease facts and figures. Alzheimers Dement. 18(4), 700–789 (2022).
  MedlineGoogle Scholar
• 10. Cummings J, Lee G, Nahed P et al. Alzheimer's disease drug development pipeline. Alzheimers Dement. 8, e12295 (2022).
  Google Scholar
• 11. Plascencia-Villa G, Perry G. Neuropathologic changes provide insights into key mechanisms related to Alzheimer disease and related dementia. Am. J. Pathol. S0002-9440(22), 00206-1 (2022).
  Google Scholar
• 12. De-Paula VJ, Radanovic M, Diniz BS et al. Alzheimer's disease. Subcell Biochem. 65, 329–352 (2012).
  Medline CASGoogle Scholar
• 13. Tiwari S, Atluri V, Kaushik A et al. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomed. 14, 5541 (2019).
  Medline CASGoogle Scholar
• 14. Chen ZR, Huang JB, Yang SL et al. Role of cholinergic signaling in Alzheimer's disease. Molecules 27(6), 1816 (2022).
  Medline CASGoogle Scholar
• 15. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5(5), 405–414 (2002).
  Medline CASGoogle Scholar
• 16. Ikonomidou C, Bosch F, Miksa M et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283(5398), 70–74 (1999).
  Medline CASGoogle Scholar
• 17. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19(2), 105–111 (1986).
  Medline CASGoogle Scholar
• 18. Brunholz S, Sisodia S, Lorenzo A et al. Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp. Brain Res. 217(3-4), 353–364 (2012).
  Medline CASGoogle Scholar
• 19. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid β peptide. Biochim. Biophys. Acta Biomembr. 1768(8), 1976–1990 (2007).
  Medline CASGoogle Scholar
• 20. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63(3), 287–303 (2009).
  Medline CASGoogle Scholar
• 21. Hernandez-Sapiens MA, Reza-Zaldívar EE, Márquez-Aguirre AL et al. Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease. Neural. Regen. Res. 17(1), 31–37 (2022).
  Medline CASGoogle Scholar
• 22. Meschia JF, Bushnell C, Boden-Albala B et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45(12), 3754–3832 (2014).
  MedlineGoogle Scholar
• 23. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke. Curr. Hypertens. Rep. 13(3), 200–207 (2011).
  Medline CASGoogle Scholar
• 24. Joas E, Bäckman K, Gustafson D et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 59(4), 796–801 (2012).
  Medline CASGoogle Scholar
• 25. Norton S, Matthews FE, Barnes DE et al. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 13(8), 788–794 (2014).
  MedlineGoogle Scholar
• 26. Cheng G, Huang C, Deng H et al. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 42(5), 484–491 (2012).
  Medline CASGoogle Scholar
• 27. Barbagallo M, Dominguez LJ. Type 2 diabetes mellitus and Alzheimer's disease. World J. Diabetes 5(6), 889 (2014).
  MedlineGoogle Scholar
• 28. Fitzpatrick AL, Kuller LH, Lopez OL et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 66(3), 336–342 (2009).
  MedlineGoogle Scholar
• 29. Magalhaes C, Carvalho M, Sousa L et al. Leptin in Alzheimer's disease. Clin. Chim. Acta 450, 162–168 (2015).
  Medline CASGoogle Scholar
• 30. Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx 1(2), 226–234 (2004).
  MedlineGoogle Scholar
• 31. Mrak RE, Griffin WST. Potential inflammatory biomarkers in Alzheimer's disease. J. Alzheimers Dis. 8(4), 369–375 (2005).
  Medline CASGoogle Scholar
• 32. Pacheco-Quinto J, de Turco EBR, De Rosa S et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels. Neurobiol. Dis. 22(3), 651–656 (2006).
  Medline CASGoogle Scholar
• 33. Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16(1), 1–13 (2004).
  Medline CASGoogle Scholar
• 34. Kniesel U, Wolburg H. Tight junctions of the blood–brain barrier. Cell. Mol. Neurobiol. 20(1), 57–76 (2000).
  Medline CASGoogle Scholar
• 35. Wolburg H, Lippoldt A. Tight junctions of the blood–brain barrier: development, composition and regulation. Vasc. Pharmacol. 38(6), 323–337 (2002).
  Medline CASGoogle Scholar
• 36. Abbott NJ, Patabendige AA, Dolman DE et al. Structure and function of the blood–brain barrier. Neurobiol. Dis. 37(1), 13–25 (2010).
  Medline CASGoogle Scholar
• 37. Barnabas W. Drug targeting strategies into the brain for treating neurological diseases. J. Neurosci. Methods 311, 133–146 (2019). • Provides details on the potential of different nanomedicine therapies for the management of Alzheimer's disease.
  Medline CASGoogle Scholar
• 38. Praça C, Rai A, Santos T et al. A nanoformulation for the preferential accumulation in adult neurogenic niches. J. Control. Rel. 284, 57–72 (2018).
  Medline CASGoogle Scholar
• 39. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov. Today 13(23–24), 1099–1106 (2008).
  Medline CASGoogle Scholar
• 40. Gaillard PJ, Visser CC, Appeldoorn CC et al. Enhanced brain drug delivery: safely crossing the blood–brain barrier. Drug Discov. Today Technol. 9(2), e155–e160 (2012).
  CASGoogle Scholar
• 41. Jones AR, Shusta EV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24(9), 1759–1771 (2007).
  Medline CASGoogle Scholar
• 42. Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood–brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J. Pharm. Sci. 14(5), 480–496 (2019).
  MedlineGoogle Scholar
• 43. Teixeira MI, Lopes C, Amaral MH et al. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur. J. Pharma. Biopharm. 149, 192–217 (2020).
  Medline CASGoogle Scholar
• 44. Hanson LR, Frey WH. Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 9(3), 1–4 (2008).
  MedlineGoogle Scholar
• 45. Samaridou E, Alonso MJ. Nose-to-brain peptide delivery – the potential of nanotechnology. Bioorg. Med. Chem. 26(10), 2888–2905 (2018).
  Medline CASGoogle Scholar
• 46. Dhuria SV, Hanson LR, Frey WH. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J. Pharmacol. Exp. Ther. 328(1), 312–320 (2009).
  Medline CASGoogle Scholar
• 47. Liu X-F, Fawcett JR, Hanson LR et al. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J. Stroke Cerebrovasc. Dis. 13(1), 16–23 (2004).
  MedlineGoogle Scholar
• 48. Binda A, Murano C, Rivolta I. Innovative therapies and nanomedicine applications for the treatment of Alzheimer's disease: a state-of-the-art (2017–2020). Int. J. Nanomed. 15, 6113–6135 (2020).
  Medline CASGoogle Scholar
• 49. Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer's disease therapy and prevention strategies. Annu. Rev. Med. 68, 413–430 (2017).
  Medline CASGoogle Scholar
• 50. Harilal S, Jose J, Parambi DGT et al. Advancements in nanotherapeutics for Alzheimer's disease: current perspectives. J. Pharm. Pharmacol. 71(9), 1370–1383 (2019).
  Medline CASGoogle Scholar
• 51. Cavazzoni P. FDA’s Decision to Approve New Treatment for Alzheimer’s Disease. MD, USA (2021).
  Google Scholar
• 52. National Institute on Aging. FDA grants accelerated approval for Alzheimer’s drug. Press release. www.nia.nih.gov/news/fda-grants-accelerated-approval-alzheimers-drug
  Google Scholar
• 53. Mudshinge SR, Deore AB, Patil S et al. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm. J. 19(3), 129–141 (2011).
  Medline CASGoogle Scholar
• 54. Ahmad ZM, Ahmad J, Amin S et al. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 13(8), 1315–1324 (2014).
  Medline CASGoogle Scholar
• 55. Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. J. Alzheimer's Dis. 13(2), 199–223 (2008).
  Medline CASGoogle Scholar
• 56. Brambilla D, Le Droumaguet B, Nicolas J et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 7(5), 521–540 (2011).
  Medline CASGoogle Scholar
• 57. Saraiva C, Praça C, Ferreira R. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J. Control. Rel. 235, 34–47 (2016).
  Medline CASGoogle Scholar
• 58. Alyautdin R, Khalin I, Nafeeza MI et al. Nanoscale drug delivery systems and the blood–brain barrier. Int. J. Nanomed. 9, 795 (2014).
  Medline CASGoogle Scholar
• 59. Fernández PL, Britton GB, Rao K. Potential immunotargets for Alzheimer's disease treatment strategies. J. Alzheimers Dis. 33(2), 297–312 (2013).
  Medline CASGoogle Scholar
• 60. Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem. Pharmacol. 88(4), 605–616 (2014).
  Medline CASGoogle Scholar
• 61. Eskici GZ, Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer's disease. Biochem 51(32), 6289–6311 (2012).
  Medline CASGoogle Scholar
• 62. Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood–brain barrier. Annu. Rev. Pharmacol. Toxicol. 55, 613–631 (2015).
  Medline CASGoogle Scholar
• 63. Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury – clinical experience in 111 patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(1), 61–67 (2005).
  Medline CASGoogle Scholar
• 64. Venkatesh K, Bullock R, Akbas A. Strategies to improve tolerability of rivastigmine: a case series. Curr. Med. Res. Opin. 23(1), 93–95 (2007). • Shows a therapeutic effect and targeted delivery of drug for the management of Alzheimer's disease.
  Medline CASGoogle Scholar
• 65. Yang Z-Z, Zhang Y-Q, Wang Z-Z et al. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 452(1–2), 344–354 (2013).
  Medline CASGoogle Scholar
• 66. Liu X, Xu K, Yan M et al. Protective effects of galantamine against Aβ-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress. Neurochem. Intern. 57(5), 588–599 (2010).
  Medline CASGoogle Scholar
• 67. Mufamadi MS, Choonara YE, Kumar P et al. Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int. J. Pharm. 448(1), 267–281 (2013).
  Medline CASGoogle Scholar
• 68. Chen H, Tang L, Qin Y et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci. 40(2), 94–102 (2010).
  Medline CASGoogle Scholar
• 69. Kuo Y-C, Wang C-T. Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin. Biomaterials 35(22), 5954–5964 (2014).
  Medline CASGoogle Scholar
• 70. Balducci C, Mancini S, Minniti S et al. Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models. J. Neuro. Sci. 34(42), 14022–14031 (2014).
  Google Scholar
• 71. Gobbi M, Re F, Canovi M et al. Lipid-based nanoparticles with high binding affinity for amyloid-β1-42 peptide. Biomaterials 31(25), 6519–6529 (2010).
  Medline CASGoogle Scholar
• 72. Matsuoka Y, Saito M, LaFrancois J et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23(1), 29–33 (2003).
  Medline CASGoogle Scholar
• 73. Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol. 7(9), 805–811 (2008).
  Medline CASGoogle Scholar
• 74. Valera E, Masliah E. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol. Ther. 138(3), 311–322 (2013).
  Medline CASGoogle Scholar
• 75. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916–919 (2000).
  Medline CASGoogle Scholar
• 76. Ordóñez-Gutiérrez L, Posado-Fernández A, Ahmadvand D et al. ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals. Biomaterials 112, 141–152 (2017).
  Medline CASGoogle Scholar
• 77. Danhier F, Ansorena E, Silva JM et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Rel. 161(2), 505–522 (2012).
  Medline CASGoogle Scholar
• 78. Sathya S, Shanmuganathan B, Saranya S et al. Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer's toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function. Artif. Cells Nanomed. Biotechnol. 46(8), 1719–1730 (2018).
  Medline CASGoogle Scholar
• 79. Fornaguera C, Feiner-Gracia N, Calderó G et al. Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7(28), 12076–12084 (2015).
  Medline CASGoogle Scholar
• 80. Sánchez-López E, Ettcheto M, Egea MA et al. New potential strategies for Alzheimer's disease prevention: PEGylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine 13(3), 1171–1182 (2017).
  Medline CASGoogle Scholar
• 81. Sánchez-López E, Ettcheto M, Egea MA et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. J. Nanobiotechnol. 16(1), 1–16 (2018).
  MedlineGoogle Scholar
• 82. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin. Pharmacokinet. 52(4), 225–241 (2013).
  Medline CASGoogle Scholar
• 83. Md S, Ali M, Baboota S et al. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 40(2), 278–287 (2014).
  MedlineGoogle Scholar
• 84. Baysal I, Ucar G, Gultekinoglu M et al. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J. Neural Transm. 124(1), 33–45 (2017).
  Medline CASGoogle Scholar
• 85. Wilson B, Samanta MK, Santhi K et al. Poly(N-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 1200, 159–168 (2008).
  Medline CASGoogle Scholar
• 86. Garrido-Maraver J, Cordero MD, Oropesa-Ávila M et al. Coenzyme Q10 therapy. Mol. Syndromol. 5(3–4), 187–197 (2014).
  Medline CASGoogle Scholar
• 87. Wang ZH, Wang ZY, Sun CS et al. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 31(5), 908–915 (2010).
  Medline CASGoogle Scholar
• 88. Toyn J. What lessons can be learned from failed Alzheimer's disease trials? Exp. Rev. Clin. Pharmacol. 8(3), 267–269 (2015).
  Medline CASGoogle Scholar
• 89. Carradori D, Balducci C, Re F et al. Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. Nanomedicine 14(2), 609–618 (2018).
  Medline CASGoogle Scholar
• 90. Jose J, Charyulu RN. Prolonged drug delivery system of an antifungal drug by association with polyamidoamine dendrimers. Int. J. Pharm. Invest. 6(2), 123 (2016).
  Medline CASGoogle Scholar
• 91. Klajnert B, Cortijo-Arellano M, Cladera J et al. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem. Biophys. Res. Commun. 345(1), 21–28 (2006).
  Medline CASGoogle Scholar
• 92. Patel DA, Henry JE, Good TA. Attenuation of β-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment. Brain Res. 1161, 95–105 (2007).
  Medline CASGoogle Scholar
• 93. Chafekar SM, Malda H, Merkx M et al. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. Chembiochem 8, 1857–1864 (2007).
  Medline CASGoogle Scholar
• 94. Aso E, Martinsson I, Appelhans D et al. Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine 17, 198–209 (2019).
  Medline CASGoogle Scholar
• 95. Chen Q, Du Y, Zhang K et al. Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer's disease. ACS Nano 12(2), 1321–1338 (2018).
  Medline CASGoogle Scholar
• 96. Karaboga MNS, Sezgintürk MK. Analysis of tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: towards Alzheimer's disease detection. Talanta 219, 121257 (2020).
  MedlineGoogle Scholar
• 97. Zhao Y, Cai J, Liu Z et al. Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer's disease mice. Nano Lett. 19(2), 674–683 (2018).
  MedlineGoogle Scholar
• 98. Sarin H. Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther. Deliv. 1(2), 289–305 (2010).
  Medline CASGoogle Scholar
• 99. Chen Y, Dalwadi G, Benson H. Drug delivery across the blood–brain barrier. Curr. Drug Deliv. 1(4), 361–376 (2004).
  Medline CASGoogle Scholar
• 100. Kang X, Chen H, Li S et al. Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability. Colloids Surf. B Biointerf. 161, 597–605 (2018).
  Medline CASGoogle Scholar
• 101. Vakilinezhad MA, Amini A, Javar HA et al. Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer's disease animal model by reducing tau hyperphosphorylation. DARU J. Pharm. Sci. 26(2), 165–177 (2018).
  CASGoogle Scholar
• 102. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res. Pharm. Sci. 13(4), 288 (2018).
  MedlineGoogle Scholar
• 103. Topal GR, Mészáros M, Porkoláb G et al. ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood–brain barrier. Pharmaceutics 13(1), 38 (2021).
  CASGoogle Scholar
• 104. Shankar PD, Shobana S, Karuppusamy I et al. A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: formation mechanism and applications. Enzyme Microb. Technol. 95, 28–44 (2016).
  Medline CASGoogle Scholar
• 105. Kim Y, Park J-H, Lee H et al. How do the size, charge and shape of nanoparticles affect amyloid β aggregation on brain lipid bilayer? Sci. Rep. 6(1), 1–14 (2016).
  Medline CASGoogle Scholar
• 106. Gao N, Sun H, Dong K et al. Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease. Chem. A Eur. J. 21(2), 829–835 (2015).
  Medline CASGoogle Scholar
• 107. Sonawane SK, Ahmad A, Chinnathambi S. Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer's disease. ACS Omega 4(7), 12833–12840 (2019).
  Medline CASGoogle Scholar
• 108. Javdani N, Rahpeyma SS, Ghasemi Y et al. Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process. Int. J. Nanomed. 14, 799 (2019).
  Medline CASGoogle Scholar
• 109. Ahmed ME, Khan MM, Javed H et al. Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Neurochem. Int. 62(4), 492–501 (2013).
  MedlineGoogle Scholar
• 110. Prakash D, Sudhandiran G. Dietary flavonoid fisetin regulates aluminium chloride-induced neuronal apoptosis in cortex and hippocampus of mice brain. J. Nut. Biochem. 26(12), 1527–1539 (2015).
  Medline CASGoogle Scholar
• 111. Khan H, Amin S, Kamal MA et al. Flavonoids as acetylcholinesterase inhibitors: current therapeutic standing and future prospects. Biomed. Pharmacother. 101, 860–870 (2018).
  Medline CASGoogle Scholar
• 112. Nabavi SF, Braidy N, Habtemariam S et al. Neuroprotective effects of chrysin: from chemistry to medicine. Neurochem. Int. 90, 224–231 (2015).
  Medline CASGoogle Scholar
• 113. Kim DH, Kim S, Jeon SJ et al. Tanshinone I enhances learning and memory, and ameliorates memory impairment in mice via the extracellular signal-regulated kinase signalling pathway. British J. Pharmacol. 158(4), 1131–1142 (2009).
  Medline CASGoogle Scholar
• 114. Uddin M, Kabir M, Niaz K et al. Molecular insight into the therapeutic promise of flavonoids against Alzheimer's disease. Molecules 25(6), 1267 (2020).
  Medline CASGoogle Scholar
• 115. Kanubaddi KR, Yang S-H, Wu L-W et al. Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation. Int. J. Nanomed. 13, 8473 (2018).
  Medline CASGoogle Scholar
• 116. Neves AR, Queiroz JF, Reis S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J. Nanobiotechnol. 14(1), 1–11 (2016).
  MedlineGoogle Scholar
• 117. Qi Y, Guo L, Jiang Y et al. Brain delivery of quercetin-loaded exosomes improved cognitive function in AD mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles. Drug Deliv. 27(1), 745–755 (2020).
  Medline CASGoogle Scholar
• 118. Pinheiro R, Granja A, Loureiro J et al. RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer's disease. Pharm. Res. 37(7), 1–12 (2020).
  Google Scholar
• 119. Pinheiro R, Granja A, Loureiro J et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease. Eur. J. Pharm. Sci. 148, 105314 (2020). • Discusses the role of nanophytomedicine as a targeted therapy for Alzheimer's disease.
  Medline CASGoogle Scholar
• 120. Ovais M, Zia N, Ahmad I et al. Phyto-therapeutic and nanomedicinal approaches to cure Alzheimer's disease: present status and future opportunities. Front. Aging Neurosci. 10, 284 (2018).
  Medline CASGoogle Scholar
• 121. Meng Q, Wang A, Hua H et al. Intranasal delivery of huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. Int. J. Nanomed. 13, 705 (2018).
  Medline CASGoogle Scholar
• 122. Li C, Tu G, Luo C et al. Effects of rhynchophylline on the hippocampal miRNA expression profile in ketamine-addicted rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 86, 379–389 (2018).
  Medline CASGoogle Scholar
• 123. Shao H, Mi Z, Ji WG et al. Rhynchophylline protects against the amyloid β-induced increase of spontaneous discharges in the hippocampal CA1 region of rats. Neurochem. Res. 40(11), 2365–2373 (2015).
  Medline CASGoogle Scholar
• 124. Fu AK, Hung KW, Huang H et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc. Natl Acad. Sci. USA 111(27), 9959–9964 (2014).
  Medline CASGoogle Scholar
• 125. Xu R, Wang J, Xu J et al. Rhynchophylline loaded-mPEG-PLGA nanoparticles coated with Tween-80 for preliminary study in Alzheimer's disease. Int. J. Nanomed. 15, 1149 (2020).
  Medline CASGoogle Scholar
• 126. Lohan S, Raza K, Mehta S et al. Anti-Alzheimer's potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence. Int. J. Pharm. 530(1–2), 263–278 (2017).
  Medline CASGoogle Scholar
• 127. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann. Indian Acad. Neurol. 11(1), 13 (2008).
  MedlineGoogle Scholar
• 128. Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280(7), 5892–5901 (2005).
  Medline CASGoogle Scholar
• 129. Baum L, Lam CWK, Cheung SK-K et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28(1), 110–113 (2008).
  MedlineGoogle Scholar
• 130. Collins AE, Saleh TM, Kalisch BE. Naturally occurring antioxidant therapy in Alzheimer's disease. Antioxidants (Basel) 11(2), 213 (2022).
  Medline CASGoogle Scholar
• 131. Sathya S, Shanmuganathan B, Devi KP. Deciphering the anti-apoptotic potential of α-bisabolol loaded solid lipid nanoparticles against Aβ induced neurotoxicity in neuro-2a cells. Colloids Surf. B Biointerf. 190, 110948 (2020).
  Medline CASGoogle Scholar
• 132. Brenza TM, Ghaisas S, Ramirez JEV et al. Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine 13(3), 809–820 (2017).
  Medline CASGoogle Scholar
• 133. Jose S, Sowmya S, Cinu T et al. Surface modified PLGA nanoparticles for brain targeting of bacoside-A. Eur. J. Pharm. Sci. 63, 29–35 (2014).
  Medline CASGoogle Scholar
• 134. Aalinkeel R, Kutscher HL, Singh A et al. Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease? J. Drug Target. 26(2), 182–193 (2018).
  Medline CASGoogle Scholar
• 135. Cano A, Ettcheto M, Chang J-H et al. Dual-drug loaded nanoparticles of epigallocatechin-3-gallate (EGCG)/ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J. Control. Rel. 301, 62–75 (2019).
  Medline CASGoogle Scholar
• 136. Doggui S, Sahni JK, Arseneault M et al. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J. Alzheimers Dis. 30(2), 377–392 (2012).
  Medline CASGoogle Scholar
• 137. Mathew A, Fukuda T, Nagaoka Y et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLOS ONE 7(3), e32616 (2012).
  Medline CASGoogle Scholar
• 138. Hu B, Dai F, Fan Z et al. Nanotheranostics: congo red/rutin-MNPs with enhanced magnetic resonance imaging and H₂O₂-responsive therapy of Alzheimer's disease in APPswe/PS1dE9 transgenic mice. Adv. Mater. 27(37), 5499–5505 (2015).
  Medline CASGoogle Scholar
• 139. Jaruszewski KM, Curran GL, Swaminathan SK et al. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials 35(6), 1967–1976 (2014).
  Medline CASGoogle Scholar
• 140. Zhang C, Wan X, Zheng X et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials 35(1), 456–465 (2014).
  Medline CASGoogle Scholar
• 141. Poplawski SG, Garbett KA, McMahan RL et al. An antisense oligonucleotide leads to suppressed transcription of Hdac2 and long-term memory enhancement. Mol. Ther. Nucleic Acids 19, 1399–1412 (2020).
  Medline CASGoogle Scholar
• 142. Mourtas S, Lazar AN, Markoutsa E et al. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. European J. Med. Chem. 80, 175–183 (2014).
  Medline CASGoogle Scholar
• 143. Papadia K, Markoutsa E, Mourtas S et al. Multifunctional LUV liposomes decorated for BBB and amyloid targeting. in vitro proof-of-concept. Eur. J. Pharm. Sci. 101, 140–148 (2017).
  Medline CASGoogle Scholar
• 144. Mourtas S, Christodoulou P, Klepetsanis P et al. Preparation of benzothiazolyl-decorated nanoliposomes. Molecules 24(8), 1540 (2019).
  Medline CASGoogle Scholar
• 145. Siegemund T, Paulke B-R, Schmiedel H et al. Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice. Int. J. Dev. Neurosci. 24(2-3), 195–201 (2006). • Provides information on self-destructed autophagy-mediated and stem cell-based therapy for the treatment of Alzheimer's disease.
  Medline CASGoogle Scholar
• 146. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J. Pathol. 221(1), 3–12 (2010).
  Medline CASGoogle Scholar
• 147. Bateman RJ, Munsell LY, Morris JC et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12(7), 856–861 (2006).
  Medline CASGoogle Scholar
• 148. Nilsson P, Saido TC. Dual roles for autophagy: degradation and secretion of Alzheimer's disease Aβ peptide. BioEssays 36(6), 570–578 (2014).
  Medline CASGoogle Scholar
• 149. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120(23), 4081–4091 (2007).
  Medline CASGoogle Scholar
• 150. Lee J-A, Beigneux A, Ahmad ST et al. ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr. Biol. 17(18), 1561–1567 (2007).
  Medline CASGoogle Scholar
• 151. Yamazaki Y, Takahashi T, Hiji M et al. Immunopositivity for ESCRT-III subunit CHMP2B in granulovacuolar degeneration of neurons in the Alzheimer's disease hippocampus. Neurosci. Lett. 477(2), 86–90 (2010).
  Medline CASGoogle Scholar
• 152. Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Harb. Perspect. 2(6), a006379 (2012).
  Google Scholar
• 153. Nixon RA, Wegiel J, Kumar A et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64(2), 113–122 (2005).
  MedlineGoogle Scholar
• 154. Yu WH, Cuervo AM, Kumar A et al. Macroautophagy – a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 171(1), 87–98 (2005).
  Medline CASGoogle Scholar
• 155. Nilsson P, Loganathan K, Sekiguchi M et al. Aβ secretion and plaque formation depend on autophagy. Cell Rep. 5(1), 61–69 (2013).
  Medline CASGoogle Scholar
• 156. Nixon RA. The role of autophagy in neurodegenerative disease. Nat. Med. 19(8), 983–997 (2013).
  Medline CASGoogle Scholar
• 157. Sarkar S. Role of autophagy in neurodegenerative diseases. Curr. Sci. 101(4), 514–519 (2011).
  CASGoogle Scholar
• 158. Zhang L, Wang L, Wang R et al. Evaluating the effectiveness of GTM-1, rapamycin, and carbamazepine on autophagy and Alzheimer disease. Med. Sci. Monit. 23, 801 (2017).
  Medline CASGoogle Scholar
• 159. Steele JW, Gandy S. Latrepirdine (Dimebon^®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 9(4), 617–618 (2013).
  Medline CASGoogle Scholar
• 160. Forlenza OV, de Paula VJ, Machado-Vieira R et al. Does lithium prevent Alzheimer's disease? Drugs Aging 29(5), 335–342 (2012).
  Medline CASGoogle Scholar
• 161. Matsunaga S, Kishi T, Annas P et al. Lithium as a treatment for Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 48(2), 403–410 (2015).
  Medline CASGoogle Scholar
• 162. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLOS ONE 10(4), e0123289 (2015).
  MedlineGoogle Scholar
• 163. Song G, Li Y, Lin L et al. Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and-independent pathways. Mol. Med. Rep. 12(5), 7615–7622 (2015).
  Medline CASGoogle Scholar
• 164. Liu D, Pitta M, Jiang H et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol. Aging 34(6), 1564–1580 (2013).
  Medline CASGoogle Scholar
• 165. Gong B, Pan Y, Vempati P et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 34(6), 1581–1588 (2013).
  Medline CASGoogle Scholar
• 166. Kickstein E, Krauss S, Thornhill P et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl Acad Sci. USA 107(50), 21830–21835 (2010).
  Medline CASGoogle Scholar
• 167. Spilman P, Podlutskaya N, Hart MJ et al. Correction: inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. PLOS ONE 6(11), e9979(2011).
  Google Scholar
• 168. Vingtdeux V, Giliberto L, Zhao H et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism. J. Biol. Chem. 285(12), 9100–9113 (2010).
  Medline CASGoogle Scholar
• 169. Porquet D, Griñán-Ferré C, Ferrer I et al. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease. J. Alzheimers Dis. 42(4), 1209–1220 (2014).
  Medline CASGoogle Scholar
• 170. Zhu Z, Yan J, Jiang W et al. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β-amyloid production and clearance. J. Neurosci. 33(32), 13138–13149 (2013).
  Medline CASGoogle Scholar
• 171. Deng M, Huang L, Ning B et al. β-asarone improves learning and memory and reduces acetyl cholinesterase and beta-amyloid 42 levels in APP/PS1 transgenic mice by regulating Beclin-1-dependent autophagy. Brain Res. 1652, 188–194 (2016).
  Medline CASGoogle Scholar
• 172. Grossi C, Rigacci S, Ambrosini S et al. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology. PLOS ONE 8(8), e71702 (2013).
  Medline CASGoogle Scholar
• 173. Martorell M, Forman K, Castro N et al. Potential therapeutic effects of oleuropein aglycone in Alzheimer's disease. Curr. Pharm. Biotechnol. 17(11), 994–1001 (2016).
  Medline CASGoogle Scholar
• 174. Inestrosa N, Tapia-Rojas C, Griffith T et al. Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing. Trans. Psychiatry 1(7), e20 (2011).
  CASGoogle Scholar
• 175. Cavieres VA, González A, Muñoz VC et al. Tetrahydrohyperforin inhibits the proteolytic processing of amyloid precursor protein and enhances its degradation by Atg5-dependent autophagy. PLOS ONE 10(8), e0136313 (2015).
  MedlineGoogle Scholar
• 176. Sarkar S, Davies JE, Huang Z et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and α-synuclein. J. Biol. Chem. 282(8), 5641–5652 (2007).
  Medline CASGoogle Scholar
• 177. Krüger U, Wang Y, Kumar S et al. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol. Aging 33(10), 2291–2305 (2012).
  Medline CASGoogle Scholar
• 178. Luo Q, Lin Y-X, Yang P-P et al. A self-destructive nanosweeper that captures and clears amyloid β-peptides. Nat. Commun. 9(1), 1–12 (2018).
  MedlineGoogle Scholar
• 179. Mytych J, Solek P, Bedzinska A et al. Klotho-mediated changes in the expression of Atg13 alter formation of ULK1 complex and thus initiation of ER- and Golgi-stress response mediated autophagy. Apoptosis 25, 57–72 (2020).
  MedlineGoogle Scholar
• 180. Mytych J, Solek P, Koziorowski M et al. Klotho modulates ER-mediated signaling crosstalk between prosurvival autophagy and apoptotic cell death during LPS challenge. Apoptosis 24, 95–107 (2019).
  Medline CASGoogle Scholar
• 181. Chen K, Sun Z. Autophagy plays a critical role in Klotho gene deficiency-induced arterial stiffening and hypertension. J. Mol. Med. 97, 1615–1625 (2019).
  Medline CASGoogle Scholar
• 182. Li D, Jing D, Liu Z et al. Enhanced expression of secreted alpha-Klotho in the hippocampus alters nesting behavior and memory formation in mice. Front. Cell. Neurosci. 13, 133 (2019).
  Medline CASGoogle Scholar
• 183. Fung TY, Iyaswamy A, Sreenivasmurthy SG et al. Klotho an autophagy stimulator as a potential therapeutic target for Alzheimer's disease: a review. Biomedicines 10(3), 705 (2022).
  Medline CASGoogle Scholar
• 184. Nixon RA. The aging lysosome: an essential catalyst for late-onset neurodegenerative diseases. Biochim. Biophys. Acta Proteins Proteom. 1868, 140443 (2020).
  Medline CASGoogle Scholar
• 185. Fernandez AF, Sebti S, Wei Y et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature 558, 136–140 (2018).
  Medline CASGoogle Scholar
• 186. Abraham CR, Mullen PC, Tucker-Zhou T et al. Klotho is a neuroprotective and cognition-enhancing protein. Vitam. Horm. 101, 215–238 (2016).
  Medline CASGoogle Scholar
• 187. Mytych J. Klotho and neurons: mutual crosstalk between autophagy, endoplasmic reticulum, and inflammatory response. Neural Regen. Res. 16, 1542–1543 (2021).
  Medline CASGoogle Scholar
• 188. Zhang F-Q, Jiang J-L, Zhang J-T et al. Current status and future prospects of stem cell therapy in Alzheimer's disease. Neural Regen. Res. 15(2), 242 (2020).
  Medline CASGoogle Scholar
• 189. Reddy PH. Current status of stem cell research: an editorial. Biochim Biophys Acta Mol Basis Dis. 1866(4), 165635 (2020).
  Medline CASGoogle Scholar
• 190. Zhang L, Dong Z-F, Zhang J-Y. Immunomodulatory role of mesenchymal stem cells in Alzheimer's disease. Life Sci. 246, 117405 (2020).
  Medline CASGoogle Scholar
• 191. Farzamfar S, Nazeri N, Salehi M et al. Will nanotechnology bring new hope for stem cell therapy? Cells Tissues Organs 206(4–5), 229–241 (2018).
  Medline CASGoogle Scholar
• 192. Ramalingam M, Haj AE, Webster TJ et al. A special section on the role of nanotechnology in stem cell research. J. Nanosci. Nanotechnol. 16(9), 8859–8861 (2016).
  CASGoogle Scholar
• 193. Santos T, Maia J, Agasse F et al. Nanomedicine boosts neurogenesis: new strategies for brain repair. Integr. Biol. 4(9), 973–981 (2012).
  CASGoogle Scholar
• 194. Teleanu DM, Chircov C, Grumezescu AM et al. Neurotoxicity of nanomaterials: an up-to-date overview. Nanomaterials 9(1), 96 (2019).
  MedlineGoogle Scholar
• 195. Bhabra G, Sood A, Fisher B et al. Nanoparticles can cause DNA damage across a cellular barrier. Nat. Nanotechnol. 4(12), 876–883 (2009).
  Medline CASGoogle Scholar
• 196. Formicola B, Cox A, Dal Magro R et al. Nanomedicine for the treatment of Alzheimer's disease. J. Biomed. Nanotechnol. 15(10), 1997–2024 (2019).
  Medline CASGoogle Scholar
• 197. Teleanu DM, Chircov C, Grumezescu AM et al. Impact of nanoparticles on brain health: an up to date overview. J. Clin. Med. 7(12), 490 (2018).
  MedlineGoogle Scholar
• 198. Carro CE, Pilozzi AR, Huang X. Nanoneurotoxicity and potential nanotheranostics for Alzheimer's disease. EC Pharmacol. Toxicol. 7(12), 1–7 (2019).
  MedlineGoogle Scholar
• 199. Kononenko V, Narat M, Drobne D. Nanoparticle interaction with the immune system. Arh. Hig. Rada Toksikol. 66(2), 97–108 (2015).
  Medline CASGoogle Scholar
• 200. Amor S, Peferoen LA, Vogel DY et al. Inflammation in neurodegenerative diseases – an update. Immunology 142(2), 151–166 (2014).
  Medline CASGoogle Scholar
• 201. Yang X, He C, Li J et al. Uptake of silica nanoparticles: neurotoxicity and Alzheimer-like pathology in human SK-N-SH and mouse neuro2a neuroblastoma cells. Toxicol. Lett. 229(1), 240–249 (2014).
  Medline CASGoogle Scholar
• 202. Sikorska K, Grądzka I, Sochanowicz B et al. Diminished amyloid-β uptake by mouse microglia upon treatment with quantum dots, silver or cerium oxide nanoparticles: nanoparticles and amyloid-β uptake by microglia. Hum. Exp. Toxicol. 39(2), 147–158 (2020).
  Medline CASGoogle Scholar
• 203. St. George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372(9634), 180–182 (2008).
  MedlineGoogle Scholar
• 204. Mangialasche F, Solomon A, Winblad B et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9(7), 702–716 (2010).
  Medline CASGoogle Scholar
• 205. Marciani DJ. Alzheimer's disease vaccine development: a new strategy focusing on immune modulation. J. Neuroimmunol. 287, 54–63 (2015).
  Medline CASGoogle Scholar
• 206. Ballard C, Lang I. Alcohol and dementia: a complex relationship with potential for dementia prevention. Lancet Public Health 3(3), e103–e104 (2018).
  MedlineGoogle Scholar
• 207. Fazil M, Md S, Haque S et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 47(1), 6–15 (2012).
  Medline CASGoogle Scholar
• 208. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur. J. Pharm. Biopharm. 76(2), 189–199 (2010).
  Medline CASGoogle Scholar
• 209. Hanafy AS, Farid RM, ElGamal SS. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain. Drug Dev. Ind. Pharm. 41(12), 2055–2068 (2015).
  Medline CASGoogle Scholar
• 210. Misra S, Chopra K, Sinha V et al. Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv. 23(4), 1434–1443 (2016).
  Medline CASGoogle Scholar
• 211. Li W, Zhou Y, Zhao N et al. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Env. Toxicol. Pharmacol. 34(2), 272–279 (2012).
  MedlineGoogle Scholar
• 212. Wilson B, Samanta MK, Santhi K et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 70(1), 75–84 (2008).
  Medline CASGoogle Scholar
• 213. Luppi B, Bigucci F, Corace G et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur. J. Pharm. Sci. 44(4), 559–565 (2011).
  Medline CASGoogle Scholar
• 214. Md S, Ali M, Ali R et al. Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation. Int. J. Biol. Macromol. 67, 418–425 (2014).
  MedlineGoogle Scholar
• 215. Shi M, Chu F, Zhu F, Zhu J. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab. Front. Aging Neurosci. 14, 870517 (2022).
  Medline CASGoogle Scholar